

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 340 750 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73

(48) Corrigendum issued on:
19.10.2005 Bulletin 2005/42

(45) Date of publication and mention
of the grant of the patent:
17.08.2005 Bulletin 2005/33

(21) Application number: **01981033.2**

(22) Date of filing: **08.11.2001**

(51) Int Cl.7: **C07D 277/40**, C07D 277/62,
C07D 277/64, C07D 277/74,
C07D 417/12, C07D 417/14,
A61K 31/426, A61K 31/427,
A61K 31/496, A61K 31/4709,
A61K 31/4725, A61K 31/428,
A61K 31/536, A61K 31/454,
A61K 31/433, A61K 31/5415,
A61K 31/439, A61P 31/22

(86) International application number:
PCT/JP2001/009790

(87) International publication number:
WO 2002/038554 (16.05.2002 Gazette 2002/20)

(54) **AMIDE DERIVATIVES**

AMIDDERIVATE

DERIVES AMIDES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

(30) Priority: **10.11.2000 JP 2000344354**

(43) Date of publication of application:
03.09.2003 Bulletin 2003/36

(73) Proprietors:
• **Astellas Pharma Inc.**
Chuo-ku, Tokyo (JP)
• **Rational Drug Design Laboratories**
Tokyo 174-8612 (JP)

(72) Inventors:
• **KONTANI, Toru,**
c/o Yamanouchi Pharma. Co., Ltd.
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **MIYATA, Junji,**
c/o Yamanouchi Pharma. Co., Ltd.
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **HAMAGUCHI, Wataru,**
c/o Yamanouchi Pharma. Co. Ltd.
Tsukuba-shi, Ibaraki 305-8585 (JP)

• **MIYAZAKI, Yoji,**
c/o Yamanouchi Pharma. Co., Ltd.
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **SUZUKI, Hiroshi,**
c/o Yamanouchi Pharma. Co., Ltd.
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **NAKAI, Eiichi, c/o Yamanouchi Pharma. Co., Ltd.**
Tsukuba-shi, Ibaraki 305-8585 (JP)
• **KAGEYAMA, Shunji,**
c/o Yamanouchi Pharma. Co., Ltd.
Tokyo 174-8612 (JP)

(74) Representative: **Bates, Philip Ian**
Reddie & Grose
16 Theobalds Road
London WC1X 8PL (GB)

(56) References cited:
WO-A1-00/29399 **WO-A1-97/24343**
WO-A1-99/42455 **US-A- 6 057 451**

• **SIMONEAU BRUNO: 'Helicase-primase**
inhibitors as novel anti-HSV agents' CHIMIA vol.
53, no. 6, 1999, pages 297 - 298, XP002908530

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 340 750 B8

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification